Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma [0.03%]
达雷木单抗单药治疗复发/难治多发性骨髓瘤后肿瘤溶解综合征的实验室指标表现
Louisa Shackleton,James Fay,Elizabeth Smyth et al.
Louisa Shackleton et al.
Case Reports
EJHaem. 2020 Jul 4;1(1):312-314. DOI:10.1002/jha2.34 2020
Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response [0.03%]
慢性粒细胞白血病患者接受尼洛替尼治疗后持续分子学反应完全缓解下的迟发性急性胰腺炎
Shifang Wang,Sai Prasad Desikan,Jay Jeffrey et al.
Shifang Wang et al.
Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy of chronic myeloid leukemia. Imatinib was the first agent utilized in the therapy of CML. Nilotinib, a second generation TKI, results in an increase in number of patient...
Case Reports
EJHaem. 2020 May 31;1(1):309-311. DOI:10.1002/jha2.21 2020
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry [0.03%]
慢性淋巴细胞白血病患者一线治疗的健康相关生活质量纵向研究：Connect®CLL登记处结果分析
Jeff P Sharman,Kim Cocks,Chadi Nabhan et al.
Jeff P Sharman et al.
Health-related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT-Le...
Kanchana De Abrew,R Ayto,J Milnthorpe
Kanchana De Abrew
A survey of extracorporeal photopheresis treatment in pediatric patients in the United Kingdom [0.03%]
英国儿童体外光化学治疗调查研究
Aisling M Flinn,Sheba Macheka,Mary Slatter et al.
Aisling M Flinn et al.
Extracorporeal photopheresis (ECP) is a second-line therapy in acute and chronic GVHD and solid organ transplant rejection. We report ECP use in 98 pediatric patients in seven UK centers from 2010 to 2017, the majority treated for aGVHD (73...
Yasuyuki Otsuka,Momoko Nishikori,Masakazu Fujimoto et al.
Yasuyuki Otsuka et al.
Intraclonal diversity is commonly observed in patients with follicular lymphoma (FL), whereas tumor cells at the onset and relapse usually share early genetic events such as VDJ rearrangement of the immunoglobulin genes and t(14;18) translo...
Case Reports
EJHaem. 2020 Jun 3;1(1):323-327. DOI:10.1002/jha2.28 2020
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib [0.03%]
一项随机、安慰剂对照、Ⅲ期临床研究：帕菲索联合硼替佐米和地塞米松治疗接受过硼替佐米治疗的复发/难治多发性骨髓瘤患者的疗效与安全性研究
Paul G Richardson,Arnon Nagler,Dina Ben-Yehuda et al.
Paul G Richardson et al.
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouragi...
Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma [0.03%]
抗BCMA双特异性抗体TNB-383B治疗复发/难治多发性骨髓瘤的体外疗效研究
David M Foureau,Manisha Bhutani,Myra Robinson et al.
David M Foureau et al.
TNB-383B is a fully human BCMA-targeting T-cell engaging bispecific monoclonal antibody (T-BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with r...
Paraneoplastic leukocytosis and thrombocytosis secondary to IL-6 elevation in metastatic melanoma [0.03%]
转移性黑色素瘤继发IL-6升高引起的副肿瘤性白细胞增多和血小板增多
Nathaniel Wilson,Cristhiam M Rojas-Hernandez
Nathaniel Wilson
DNMT1 and p38γ are inversely expressed in reactive non-metastatic lymph nodes burdened with colorectal adenocarcinoma [0.03%]
DNMT1 和 p38γ 在携带结肠腺癌的反应性非转移淋巴结中的表达呈负相关关系
Xu Hannah Zhang,Zhirong Yin,Aimin Zhang et al.
Xu Hannah Zhang et al.
Lymph nodes are important front-line defense immune tissues, which also act against inflammatory diseases and cancer. Lymph nodes undergo extensive upheavals within newly formed germinal centers (GCs) when exposed to antigens, the molecular...